【美国生物制药公司Fusion Pharmaceuticals(FUSN.US)今日盘前股价飙涨94%,报20.65美元。据悉,阿斯利康计划斥资约20亿美元现金收购Fusion Pharmaceuticals,以扩大其肿瘤产品组合。交易价格为每股21美元,较周一收盘价溢价逾97%。此外,阿斯利康还将支付每股3美元的不可转让或有价值权,使整个交易价值达到约24亿美元。】 和讯自...
美股盘前三大股指期货走低,道指期货暂跌0.05%;热门中概股盘前涨跌互现;阿斯利康将以20亿美元现金收购Fusion Pharmaceuticals;辉瑞拟以 7.85美元/股增发Haleon股票;华米科技Q4营收同比下降44.0% 。
Singh covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Eloxx Pharmaceuticals, and Viracta Therapeutics. Currently, the analyst consensus on Biomea Fusion is a Strong Buy with an average price target of $47.20. See the top stocks recommended by...
Several monoclonal antibody (mAb)-based therapies, including those developed by Regeneron Pharmaceuticals (REGEN-COV) and Eli Lilly (bamlanivimab and etesevimab together), have also been authorized by the FDA for emergency use against COVID-19; however, their high costs and limited accessibility ...
Stock price prediction has long been a topic of interest in academia and the financial industry. Numerous factors influence stock prices, such as a company’s performance, industry development, national policies, and other macroeconomic factors. These factors are challenging to quantify, making predicti...
Kalcheva-Yovkova, E.; Valkova, I.V.; Vassilev, N.; et al. Design, Synthesis, In Silico Studies and In Vitro Evaluation of New Indole- and/or Donepezil-like Hybrids as Multitarget-Directed Agents for Alzheimer’s Disease.Pharmaceuticals2023,16, 1194. [Google Scholar] [CrossRef] [PubMed...